Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at NanoView Biosciences, Ulitvue, ‘All of Us’ Program, More

NanoView Biosciences: Jan Lötvall, Mark Plavsic 

NanoView Biosciences, a developer of liquid biopsy technologies, has appointed Jan Lötvall and Mark Plavsic to the company's scientific advisory board. Lötvall is a professor at the University of Gothenburg in Sweden. He directs a research lab studying extracellular vesicles and is a medical specialist in both clinical allergy and clinical pharmacology, with experience in translational studies of inflammation and cancer. Lötvall is the founding editor and current editor-in-chief of the Journal of Extracellular Vesicles and has previously served as chief scientist at Codiak BioSciences. 

Plavsic is the chief technical officer at Fate Therapeutics. He has also previously served as CTO at Lysogene, head of product safety and global manufacturing process improvement in Sanofi Genzyme's Technical Operations unit, and head of gene therapy development in the same company's Technology Development unit.

Ultivue: Fenel Eloi, Mary Pat Lancelotta 

Ultivue, a provider of multiplex biomarker assays for tissue phenotyping and digital pathology, has added Fenel Eloi and Mary Pat Lancelotta as independent board members. Eloi has served as CFO and chief operating officer at Cell Signaling Technology from 2005 to 2018. He currently serves on the board of directors and chairs the audit committee of 908 Devices. He also serves on the board of directors of MitoTherapeutix. 

Lancelotta is currently vice president of corporate marketing and communications at Adaptive Biotechnologies. Prior to this, she led corporate and product marketing for Foundation Medicine. Before that, she led corporate and strategic initiatives and strategic planning at Quest Diagnostics. Lancelotta is also on the board of directors of Molecular Match and the TargetCancer Foundation.

All of Us Research Program: Karriem Watson

Karriem Watson has been named chief engagement officer of the National Institutes of Health's All of Us research program. He comes to the population health project from Mile Square Health Center, which is affiliated with the University of Illinois Hospital and Health Sciences System, where he was associate executive director. He also served as associate director of community outreach and engagement at the University of Illinois Cancer Center and as research assistant professor in the University of Illinois Chicago School of Public Health. In addition, he was co-lead of the All of Us Engagement Core at the Meharry-Vanderbilt Alliance. Watson holds a doctorate in health sciences from Nova Southeastern University School of Health Sciences, a master of science degree in basic medical science from Wayne State University School of Medicine, a master of public health from the University of Illinois at Chicago, and a bachelor's degree in biology from the University of Michigan.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.